<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:56:55Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9788816" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9788816</identifier>
        <datestamp>2022-12-30</datestamp>
        <setSpec>rheumatology</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="iso-abbrev">Rheumatology (Oxford)</journal-id>
              <journal-id journal-id-type="publisher-id">brheum</journal-id>
              <journal-title-group>
                <journal-title>Rheumatology (Oxford, England)</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1462-0324</issn>
              <issn pub-type="epub">1462-0332</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9788816</article-id>
              <article-id pub-id-type="pmcid">PMC9788816</article-id>
              <article-id pub-id-type="pmc-uid">9788816</article-id>
              <article-id pub-id-type="pmid">35583273</article-id>
              <article-id pub-id-type="pmid">35583273</article-id>
              <article-id pub-id-type="doi">10.1093/rheumatology/keac300</article-id>
              <article-id pub-id-type="publisher-id">keac300</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Science</subject>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00360</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3975-8938</contrib-id>
                  <name>
                    <surname>Denton</surname>
                    <given-names>Christopher P</given-names>
                  </name>
                  <aff><institution>Centre for Rheumatology and Connective Tissue Diseases, Division of Medicine, University College London</institution>, London</aff>
                  <xref rid="keac300-cor1" ref-type="corresp"/>
                  <!--c.denton@ucl.ac.uk-->
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8528-2283</contrib-id>
                  <name>
                    <surname>del Galdo</surname>
                    <given-names>Francesco</given-names>
                  </name>
                  <aff><institution>Institute of Rheumatic and Musculoskeletal Medicine, and Biomedical Research Centre, University of Leeds</institution>, Leeds, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Khanna</surname>
                    <given-names>Dinesh</given-names>
                  </name>
                  <aff><institution>Scleroderma Program, University of Michigan</institution>, Ann Arbor, MI, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vonk</surname>
                    <given-names>Madelon C</given-names>
                  </name>
                  <aff><institution>Department of Rheumatology, Radboud University Medical Center</institution>, Nijmegen, <country country="NL">The Netherlands</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chung</surname>
                    <given-names>Lorinda</given-names>
                  </name>
                  <aff><institution>Stanford University School of Medicine and Palo Alto VA Health Care System</institution>, Palo Alto, CA, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Johnson</surname>
                    <given-names>Sindhu R</given-names>
                  </name>
                  <aff>
                    <institution>Toronto Scleroderma Program, Toronto Western Hospital</institution>
                  </aff>
                  <aff><institution>Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto</institution>, Toronto, ON, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Varga</surname>
                    <given-names>John</given-names>
                  </name>
                  <aff><institution>Scleroderma Program, University of Michigan</institution>, Ann Arbor, MI, <country country="US">USA</country></aff>
                  <aff><institution>Department of Medicine, Feinberg School of Medicine, Northwestern University</institution>, Chicago, IL</aff>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7857-2373</contrib-id>
                  <name>
                    <surname>Furst</surname>
                    <given-names>Daniel E</given-names>
                  </name>
                  <aff><institution>University of California</institution>, Los Angeles, Los Angeles, CA</aff>
                  <aff><institution>University of Washington</institution>, Seattle, WA, <country country="US">USA</country></aff>
                  <aff><institution>University of Florence</institution>, Florence, <country country="IT">Italy</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Temple</surname>
                    <given-names>Jane</given-names>
                  </name>
                  <aff><institution>GlaxoSmithKline</institution>, Uxbridge</aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zecchin</surname>
                    <given-names>Chiara</given-names>
                  </name>
                  <aff><institution>GlaxoSmithKline</institution>, Stevenage, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Csomor</surname>
                    <given-names>Eszter</given-names>
                  </name>
                  <aff><institution>GlaxoSmithKline</institution>, Stevenage, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Amy</given-names>
                  </name>
                  <aff><institution>GlaxoSmithKline</institution>, Mississauga, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wisniacki</surname>
                    <given-names>Nicolas</given-names>
                  </name>
                  <aff><institution>GlaxoSmithKline</institution>, Stevenage, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Flint</surname>
                    <given-names>Shaun M</given-names>
                  </name>
                  <aff><institution>GlaxoSmithKline</institution>, Stevenage, <country country="GB">UK</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Reid</surname>
                    <given-names>Juliet</given-names>
                  </name>
                  <aff><institution>GlaxoSmithKline</institution>, Stevenage, <country country="GB">UK</country></aff>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="keac300-cor1">Correspondence to: Christopher Denton, Centre for Rheumatology and Connective Tissue Diseases, University College London, Division of Medicine, Rowland Hill Street, London NW3 2PF, UK. E-mail: <email>c.denton@ucl.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <month>1</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-05-18">
                <day>18</day>
                <month>5</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>18</day>
                <month>5</month>
                <year>2022</year>
              </pub-date>
              <volume>62</volume>
              <issue>1</issue>
              <fpage>234</fpage>
              <lpage>242</lpage>
              <history>
                <date date-type="received">
                  <day>02</day>
                  <month>2</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>19</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>12</day>
                  <month>6</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="keac300.pdf"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s1">
                  <title>Objectives</title>
                  <p>The cytokine oncostatin M (OSM) is implicated in the pathology of SSc. Inhibiting OSM signalling using GSK2330811 (an anti-OSM monoclonal antibody) in patients with SSc has the potential to slow or stop the disease process.</p>
                </sec>
                <sec id="s2">
                  <title>Methods</title>
                  <p>This multicentre, randomized, double-blind, placebo-controlled study enrolled participants ≥18 years of age with active dcSSc. Participants were randomized 3:1 (GSK2330811:placebo) in one of two sequential cohorts to receive GSK2330811 (cohort 1: 100 mg; cohort 2: 300 mg) or placebo s.c. every other week for 12 weeks. The primary endpoint was safety; blood and skin biopsy samples were collected to explore mechanistic effects on inflammation and fibrosis. Clinical efficacy was an exploratory endpoint.</p>
                </sec>
                <sec id="s3">
                  <title>Results</title>
                  <p>Thirty-five participants were randomized to placebo (<italic toggle="yes">n</italic> = 8), GSK2330811 100 mg (<italic toggle="yes">n</italic> = 3) or GSK2330811 300 mg (<italic toggle="yes">n</italic> = 24). Proof of mechanism, measured by coordinate effects on biomarkers of inflammation or fibrosis, was not demonstrated following GSK2330811 treatment. There were no meaningful differences between GSK2330811 and placebo for any efficacy endpoints. The safety and tolerability of GSK2330811 were not favourable in the 300 mg group, with on-target, dose-dependent adverse events related to decreases in haemoglobin and platelet count that were not observed in the 100 mg or placebo groups.</p>
                </sec>
                <sec id="s4">
                  <title>Conclusion</title>
                  <p>Despite a robust and novel experimental medicine approach and evidence of target engagement, anticipated SSc-related biologic effects of GSK2330811 were not different from placebo and safety was unfavourable, suggesting OSM inhibition may not be a useful therapeutic strategy in SSc.</p>
                </sec>
                <sec id="s5">
                  <title>Trial registration number</title>
                  <p>ClinicalTrials.gov, NCT03041025; EudraCT, 2016-003417-95.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>biomarkers</kwd>
                <kwd>fibrosis</kwd>
                <kwd>GSK2330811</kwd>
                <kwd>inflammation</kwd>
                <kwd>monoclonal antibody</kwd>
                <kwd>placebo-controlled trial</kwd>
                <kwd>safety</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>GlaxoSmithKline</institution>
                      <institution-id institution-id-type="DOI">10.13039/100004330</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>NCT03041025</award-id>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Proof of Mechanism Study</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>GSK2330811</award-id>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Diffuse Cutaneous Systemic Sclerosis</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="9"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>
              <boxed-text id="keac300-BOX1" position="float">
                <label>Rheumatology key messages</label>
                <list list-type="bullet">
                  <list-item>
                    <p>Preclinical evidence suggests that OSM is a cytokine implicated in the pathogenesis of SSc.</p>
                  </list-item>
                  <list-item>
                    <p>OSM inhibition by GSK2330811 did not modulate biomarkers of inflammation or fibrosis in SSc patients.</p>
                  </list-item>
                  <list-item>
                    <p>This study advances understanding of OSM biology and provides valuable insights into SSc trial design.</p>
                  </list-item>
                </list>
              </boxed-text>
            </p>
            <sec>
              <title>Introduction</title>
              <p>Diffuse cutaneous SSc (dcSSc) is a systemic autoimmune rheumatic disorder characterized by dysregulated immune response and progressive fibrosis of the skin and internal organs [<xref rid="keac300-B1" ref-type="bibr">1</xref>, <xref rid="keac300-B2" ref-type="bibr">2</xref>]. Nintedanib [<xref rid="keac300-B3" ref-type="bibr">3</xref>] and tocilizumab [<xref rid="keac300-B4" ref-type="bibr">4</xref>] are licenced for the treatment of SSc-associated interstitial lung disease (ILD) and haematopoietic stem cell transplantation can improve skin thickening, progression-free survival and long-term survival [<xref rid="keac300-B5" ref-type="bibr">5</xref>, <xref rid="keac300-B6" ref-type="bibr">6</xref>]. However, effective disease-modifying therapies are needed [<xref rid="keac300-B7" ref-type="bibr">7</xref>].</p>
              <p>Oncostatin M (OSM) is a member of the IL-6 cytokine family with a potentially important role in the pathogenesis of SSc. OSM levels are elevated in the serum of patients with SSc [<xref rid="keac300-B8" ref-type="bibr">8</xref>] and OSM receptor expression in the skin of patients with SSc is associated with more rapid progression of skin disease [<xref rid="keac300-B9" ref-type="bibr">9</xref>]. OSM induces a profibrotic response in human skin organoid and murine models [<xref rid="keac300-B10" ref-type="bibr">10–14</xref>] that may be driven in part by an increase in profibrotic M2-like macrophages [<xref rid="keac300-B11" ref-type="bibr">11</xref>].</p>
              <p>GSK2330811, a humanized IgG1 monoclonal antibody, prevents OSM receptor binding. It was well tolerated in healthy volunteers following single s.c. doses of 0.1–6 mg/kg [<xref rid="keac300-B15" ref-type="bibr">15</xref>]. This is the first study of GSK2330811 in participants with SSc and investigated the safety, tolerability, pharmacokinetics (PK) and target engagement following repeat dosing. To explore mechanistic efficacy, we used multivariate modelling of biomarkers that reflect the anticipated mechanism of action of GSK2330811, representing a rigorous statistical framework for investigation of experimental medicine in complex immune-mediated disease.</p>
            </sec>
            <sec>
              <title>Materials and methods</title>
              <p>Additional methods are provided in the <xref rid="sup1" ref-type="supplementary-material">Supplementary Methods</xref>, available at <italic toggle="yes">Rheumatology</italic> online. Full study details are available in the protocol (<xref rid="sup1" ref-type="supplementary-material">Supplementary File S1</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
              <sec>
                <title>Study design</title>
                <p>This was a phase 2a, multicentre, randomized, double-blind (sponsor open), placebo-controlled, proof of mechanism study in adults with dcSSc conducted at 14 centres across four countries (Canada, the Netherlands, UK and USA) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <p>The study comprised a ≤6 week screening period, a 12 week treatment period and a 16 week post-treatment follow-up. Eligible participants were randomized (3:1) to six doses of s.c. GSK2330811 or placebo, administered every other week in one of two sequential cohorts, each with a block size of four: GSK2330811 100 mg or placebo (cohort 1) or GSK2330811 300 mg or placebo (cohort 2, stratified according to mycophenolate use).</p>
              </sec>
              <sec>
                <title>Study population</title>
                <p>Eligible participants were ≥18 years of age with active dcSSc and a modified Rodnan skin score (mRSS) ≥10 and ≤35 at screening and ≤5 years from onset of the first non-RP manifestation. Active SSc was defined as meeting at least one of the following criteria during screening: CRP ≥6 mg/l, disease duration ≤18 months (from the first non-RP manifestation), or any of the following within the previous 6 months: increase of ≥3 mRSS units, involvement of one new body area and an increase of ≥2 mRSS units, or involvement of two new body areas. Participants taking mycophenolate were eligible if they had been on a stable dosage for ≥3 months prior to the first dosing day and were willing to continue this dosage until the day 85 visit.</p>
              </sec>
              <sec>
                <title>Endpoints</title>
                <p>The primary endpoint was safety and tolerability. Secondary endpoints were PK, target engagement in blood and anti-drug antibodies (ADA). Exploratory endpoints included biomarkers of fibrosis, inflammation and vasculopathy in the blood and skin and clinical endpoints.</p>
              </sec>
              <sec>
                <title>PK and target engagement</title>
                <p>Blood samples were collected on days 1, 15, 29, 57, 85, 113, 155 and 197. A skin suction blister was optional for participants in cohort 2 and performed on day 57–85 as previously described [<xref rid="keac300-B15" ref-type="bibr">15</xref>]. The GSK2330811 concentration and free and total OSM in blood and skin blister fluid samples were analysed using validated assays [<xref rid="keac300-B15" ref-type="bibr">15</xref>]. Individual dosing information and parameters from a minimal physiologically based PK (mPBPK) and target engagement model [<xref rid="keac300-B15" ref-type="bibr">15</xref>] were used to simulate exposure and total and free OSM and derive the percentage target engagement [(1−free OSM/baseline OSM)*100].</p>
              </sec>
              <sec>
                <title>Biomarkers</title>
                <p>Four key biomarkers of inflammation and fibrosis were prespecified for analysis to determine proof of mechanism: alpha smooth muscle actin (αSMA) [<xref rid="keac300-B16" ref-type="bibr">16–19</xref>] measured by skin histology, 2-gene skin score (2GSSC) [<xref rid="keac300-B19" ref-type="bibr">19–21</xref>] derived from measurement of THBS1 and MS4A4A mRNA in the skin; procollagen type III N-terminal peptide (PIIINP) [<xref rid="keac300-B17" ref-type="bibr">17</xref>, <xref rid="keac300-B22" ref-type="bibr">22–28</xref>] measured in serum and C-C motif chemokine ligand 2 (CCL2) [<xref rid="keac300-B20" ref-type="bibr">20</xref>, <xref rid="keac300-B21" ref-type="bibr">21</xref>, <xref rid="keac300-B29" ref-type="bibr">29</xref>] measured by mRNA in skin. These markers were selected based on the strength of evidence for modulation by OSM, differentiation between SSc and healthy populations, correlation with clinical endpoints and response to other therapies within 6 months [<xref rid="keac300-B16" ref-type="bibr">16</xref>, <xref rid="keac300-B19" ref-type="bibr">19</xref>, <xref rid="keac300-B20" ref-type="bibr">20</xref>, <xref rid="keac300-B28" ref-type="bibr">28</xref>]. Serum IL-6, CRP and CCL2 levels and suppressor of cytokine signalling-3 (SOCS3) mRNA in skin were used as pharmacodynamic biomarkers of OSM signalling. Serum, plasma and skin punch biopsies were collected for biomarker assessment.</p>
              </sec>
              <sec>
                <title>Clinical endpoints</title>
                <p>Among others, mRSS and forced vital capacity (FVC) measured by respiratory laboratory tests (FVC<sub>lab</sub>) and home spirometry (FVC<sub>home</sub>) were exploratory endpoints.</p>
              </sec>
              <sec>
                <title>Statistical analyses</title>
                <p>Sample size was based on feasibility, with the intention of randomizing 24–36 participants to cohort 2. No formal analyses were performed for safety. As the study was not designed for formal hypothesis testing, an estimation approach was taken. Bayesian analyses used non-informative priors, adjusting for mycophenolate use at day 1 and including terms for baseline. Longitudinal analysis was adjusted for visit, visit by treatment and visit by baseline interactions. Change from baseline to day 85 data for the four prespecified biomarkers (αSMA, 2GSSC, PIIINP and CCL2) were analysed using a multivariate model, adjusted for the corresponding baseline value and treatment. The study would be considered negative for proof of mechanism if the joint probability of a change from baseline for all combinations of three biomarkers was &lt;50%. Spearman correlation coefficients were calculated for the baseline:change from baseline ratio by treatment group. No missing data were imputed.</p>
              </sec>
              <sec>
                <title>Ethics approval and patient involvement</title>
                <p>The study protocol was approved by each study site’s ethics committee or institutional review board, in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), Good Clinical Practice (GCP) and applicable country-specific requirements.</p>
              </sec>
            </sec>
            <sec>
              <title>Results</title>
              <sec>
                <title>Participant disposition and baseline characteristics</title>
                <p>The first participant enrolled on 22 June 2017 and the last participant completed the study on 7 July 2020. Of the 47 participants screened, 35 were eligible (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S1</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <p>Of the 35 participants, 26 (74%) were women and the median disease duration from first non-RP symptom was 16 months (range 4–60). Most participants were taking mycophenolate at entry [<italic toggle="yes">n</italic> = 29 (83%)], with balanced use between the placebo and GSK2330811 300 mg groups. Study groups were similar at baseline, except the placebo group comprised fewer patients with ILD and had a higher mean FVC than the GSK2330811 300 mg group (<xref rid="keac300-T1" ref-type="table">Table 1</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <table-wrap position="float" id="keac300-T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Participant demographics and clinical characteristics at baseline (safety population, unless stated otherwise)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Characteristics</th>
                        <th rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 8)</th>
                        <th rowspan="1" colspan="1">GSK2330811 100 mg (<italic toggle="yes">n</italic> = 3)<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></th>
                        <th rowspan="1" colspan="1">GSK2330811 300 mg (<italic toggle="yes">n</italic> = 24)</th>
                        <th rowspan="1" colspan="1">Total (<italic toggle="yes">N</italic> = 35)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">Age, years, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">50.8 (15.4)</td>
                        <td rowspan="1" colspan="1">66.7 (NA)</td>
                        <td rowspan="1" colspan="1">52.6 (12.6)</td>
                        <td rowspan="1" colspan="1">53.4 (13.2)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Female, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">6 (75)</td>
                        <td rowspan="1" colspan="1">1 (33)</td>
                        <td rowspan="1" colspan="1">19 (79)</td>
                        <td rowspan="1" colspan="1">26 (74)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Race, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> White</td>
                        <td rowspan="1" colspan="1">7 (88)</td>
                        <td rowspan="1" colspan="1">3 (100)</td>
                        <td rowspan="1" colspan="1">20 (83)</td>
                        <td rowspan="1" colspan="1">30 (86)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Black or African American</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">3 (13)</td>
                        <td rowspan="1" colspan="1">3 (9)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Asian</td>
                        <td rowspan="1" colspan="1">1 (13)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> American Indian or Alaska Native</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (4)</td>
                        <td rowspan="1" colspan="1">1 (3)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>, mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">23.9 (4.1)</td>
                        <td rowspan="1" colspan="1">27.9 (NA)</td>
                        <td rowspan="1" colspan="1">29.4 (6.7)</td>
                        <td rowspan="1" colspan="1">28.0 (6.4)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Time since onset of first non-Raynaud manifestation of disease, months, median (range)</td>
                        <td rowspan="1" colspan="1">12.0 (7–21)</td>
                        <td rowspan="1" colspan="1">14.0 (11–21)</td>
                        <td rowspan="1" colspan="1">17.5 (4–60)</td>
                        <td rowspan="1" colspan="1">16.0 (4–60)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Pulmonary fibrosis<xref rid="tblfn3" ref-type="table-fn"><sup>c</sup></xref>, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">1 (13)</td>
                        <td rowspan="1" colspan="1">1 (33)</td>
                        <td rowspan="1" colspan="1">8 (33)</td>
                        <td rowspan="1" colspan="1">10 (29)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Mycophenolate use at day 1, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1">7 (88)</td>
                        <td rowspan="1" colspan="1">2 (67)</td>
                        <td rowspan="1" colspan="1">20 (83)<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1">29 (83)<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline mRSS</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">20.5 (4.5)</td>
                        <td rowspan="1" colspan="1">32.0 (NA)</td>
                        <td rowspan="1" colspan="1">20.5 (6.6)</td>
                        <td rowspan="1" colspan="1">21.5</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Median (range)</td>
                        <td rowspan="1" colspan="1">19 (16–29)</td>
                        <td rowspan="1" colspan="1">31 (29–36)</td>
                        <td rowspan="1" colspan="1">19 (11–32)</td>
                        <td rowspan="1" colspan="1">19 (11–36)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline FVC (% predicted)<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">105 (23.1)</td>
                        <td rowspan="1" colspan="1">104 (NA)</td>
                        <td rowspan="1" colspan="1">87.7 (18.6)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Median (range)</td>
                        <td rowspan="1" colspan="1">104 (79–155)</td>
                        <td rowspan="1" colspan="1">105 (103–105)</td>
                        <td rowspan="1" colspan="1">87 (54–129)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline DLCO (% haemoglobin)<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref>, corrected</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">78.8 (22.7)</td>
                        <td rowspan="1" colspan="1">89.0 (NA)</td>
                        <td rowspan="1" colspan="1">72.6 (18.7)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Median (range)</td>
                        <td rowspan="1" colspan="1">72 (55–126)</td>
                        <td rowspan="1" colspan="1">88 (80–99)</td>
                        <td rowspan="1" colspan="1">69 (44–123)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline CRP, mg/L,<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref> median (range)</td>
                        <td rowspan="1" colspan="1">2.0 (0.1–11.6)</td>
                        <td rowspan="1" colspan="1">2.1 (0.7–3.3)</td>
                        <td rowspan="1" colspan="1">1.7 (0.2–82.5)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline PhGA,<sup>a</sup> median (range)</td>
                        <td rowspan="1" colspan="1">3.5 (2–7)</td>
                        <td rowspan="1" colspan="1">2.0 (2–6)</td>
                        <td rowspan="1" colspan="1">4.0 (0–7)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline PtGA,<xref rid="tblfn1" ref-type="table-fn"><sup>a</sup></xref><sup>,</sup><xref rid="tblfn4" ref-type="table-fn"><sup>d</sup></xref> median (range)</td>
                        <td rowspan="1" colspan="1">2.0 (0–5)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">5.0 (1–8)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">Baseline autoantibody profile, <italic toggle="yes">n</italic> (%)</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> ANA</td>
                        <td rowspan="1" colspan="1">8 (100)</td>
                        <td rowspan="1" colspan="1">3 (100)</td>
                        <td rowspan="1" colspan="1">21 (88)</td>
                        <td rowspan="1" colspan="1">32 (91)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Anti-RNA polymerase III</td>
                        <td rowspan="1" colspan="1">5 (63)</td>
                        <td rowspan="1" colspan="1">2 (67)</td>
                        <td rowspan="1" colspan="1">8 (33)</td>
                        <td rowspan="1" colspan="1">15 (43)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Anti-Scl-70</td>
                        <td rowspan="1" colspan="1">2 (25)</td>
                        <td rowspan="1" colspan="1">1 (33)</td>
                        <td rowspan="1" colspan="1">4 (17)</td>
                        <td rowspan="1" colspan="1">7 (20)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Anti-centromere</td>
                        <td rowspan="1" colspan="1">1 (13)</td>
                        <td rowspan="1" colspan="1">0</td>
                        <td rowspan="1" colspan="1">1 (4)</td>
                        <td rowspan="1" colspan="1">2 (6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn1">
                      <label>a</label>
                      <p>Data from the per-protocol population where one participant in the GSK2330811 300 mg group was excluded (<italic toggle="yes">n</italic> = 23).</p>
                    </fn>
                    <fn id="tblfn2">
                      <label>b</label>
                      <p><sc>s</sc>.<sc>d</sc>. not calculated in the GSK2330811 100 mg group, as there were only three participants.</p>
                    </fn>
                    <fn id="tblfn3">
                      <label>c</label>
                      <p>Confirmed by high-resolution CT.</p>
                    </fn>
                    <fn id="tblfn4">
                      <label>d</label>
                      <p>Data missing from one participant in the placebo group (<italic toggle="yes">n</italic> = 7) and two participants in the GSK2330811 100 mg group (<italic toggle="yes">n</italic> = 1).</p>
                    </fn>
                    <fn id="tblfn5">
                      <p>DLCO: diffusing capacity of the lungs for carbon monoxide; NA: not applicable; PhGA: Physician’s Global Assessment; PtGA: Patient’s Global Assessment.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>PK, target engagement and anti-drug antibodies</title>
                <p>GSK2330811 plasma concentrations are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S3</xref>, available at <italic toggle="yes">Rheumatology</italic> online. GSK2330811 concentrations in the two available skin blister fluid samples in the 300 mg group were 3293 ng/ml and 11 154 ng/ml.</p>
                <p>Model parameter values from the mPBPK model are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S4</xref>, available at <italic toggle="yes">Rheumatology</italic> online. The value of the model-predicted baseline OSM parameter was updated to reflect serum baseline OSM measured in this study (geometric mean 0.000957 nM; geometric coefficient of variation 59%). During the on-treatment phase, free OSM levels in serum were below the lower limit of quantitation (LLQ) in the 300 mg group, therefore the model-predicted free OSM concentration was used to derive target engagement. Mean serum total OSM levels increased after GSK2330811 dosing, suggesting GSK2330811–OSM binding and target engagement [<xref rid="keac300-B15" ref-type="bibr">15</xref>] (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2A</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Total:baseline OSM ratios for the 300 mg group are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref>, available at <italic toggle="yes">Rheumatology</italic> online. The median (80% interval) model-derived target engagement in serum for this group was estimated at 91% (range 81–94%) on day 77. In the skin blister fluid, free OSM from two participants in the 300 mg group were below the LLQ; their total OSM values were 249.13 and 199.28 pg/ml.</p>
                <p>Model-derived target engagement was predicted to be 87% (range 77–92) in well-perfused tissues and 67% (range 51–78) in poorly perfused tissues, but too few skin blister fluid samples were collected to estimate this directly for fibrotic skin.</p>
                <p>In the GSK2330811 300 mg group, two (9%) participants were positive for ADA at any time post-baseline and all were negative for ADA at their final study visit. In the placebo and 100 mg groups, no participants were ADA positive any time post-baseline.</p>
              </sec>
              <sec>
                <title>Biomarkers</title>
                <p>Despite evidence of target engagement in serum following administration of GSK2330811 300 mg, there were no changes from baseline in SOCS3 in the skin (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2B</xref>, available at <italic toggle="yes">Rheumatology</italic> online) or IL-6, CRP or CCL2 in serum (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S2C–E</xref>, available at <italic toggle="yes">Rheumatology</italic> online). No changes were observed for other disease and OSM-related genes analysed in the skin (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S6</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <p>No reduction of potential markers of inflammation or fibrosis (αSMA, CCL2, 2GSSC and PIIINP) was observed from baseline to day 85 for the GSK2330811 300 mg group (<xref rid="keac300-F1" ref-type="fig">Fig. 1</xref>). The jointly modelled probability that, based on the observed data, the reduction from baseline in at least three of four of these biomarkers was non-zero was 37%, which did not meet the prespecified 50% threshold. Although a difference from placebo was observed for αSMA, only three participants in the placebo group had sufficient skin biopsy tissue. Changes in key individual biomarkers following GSK2330811 300 mg were not well correlated (correlation coefficient &lt;0.4; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S7</xref>, available at <italic toggle="yes">Rheumatology</italic> online); results from the univariate and multivariate models were similar for the fitted estimates (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S8</xref>, available at <italic toggle="yes">Rheumatology</italic> online) and the probability of a change in the biomarkers (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S9</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <fig position="float" id="keac300-F1">
                  <label><sc>Fig</sc>. 1</label>
                  <caption>
                    <p>(<bold>A–C</bold>) Ratio to baseline at day 85 and (<bold>D</bold>) including visits up to day 85<sup>a</sup></p>
                    <p>(<bold>A–C</bold>) Posterior medians are based on a Bayesian analysis at day 85 only. (<bold>D</bold>) Posterior medians are based on a Bayesian longitudinal analysis. <sup>a</sup>Per protocol population. αSMA: alpha smooth muscle actin; CCL2: C-C motif chemokine ligand 2; PIIINP: procollagen type III N-terminal peptide; </p>
                    <p>2GSSC: 2-gene skin score; BL: baseline; CrI: credible interval.</p>
                  </caption>
                  <graphic xlink:href="keac300f1" position="float"/>
                </fig>
                <p>Of 22 biomarkers analysed in blood, only 3 (tissue inhibitor of metalloproteinases 1, soluble vascular cell adhesion molecule-1, vascular endothelial growth factor) showed a marginal change (≤1.3-fold) following GSK2330811 300 mg dosing that was not seen in the placebo group (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S3</xref>, available at <italic toggle="yes">Rheumatology</italic> online). GSK2330811 showed no effect on M1 and M2 macrophage and fibrosis gene signatures in skin (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S4</xref> and <xref rid="sup1" ref-type="supplementary-material">Table S10</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
              </sec>
              <sec>
                <title>Clinical endpoints</title>
                <p>The mean change from baseline mRSS at day 85 showed no difference between the GSK2330811 300 mg and placebo groups (<xref rid="keac300-T2" ref-type="table">Table 2</xref>). No meaningful differences between the GSK2330811 300 mg and placebo groups were reported for any other clinical endpoint, including FVC<sub>home</sub> (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S5</xref>, available at <italic toggle="yes">Rheumatology</italic> online) or measures of participants’ health (<xref rid="keac300-T2" ref-type="table">Table 2</xref>; <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S11</xref>, available at <italic toggle="yes">Rheumatology</italic> online). A <italic toggle="yes">post hoc</italic> analysis indicated that FVC<sub>home</sub> and FVC<sub>lab</sub> measurements were highly correlated (correlation coefficients 0.8 at baseline and 0.9 at day 85) (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S6</xref>, available at <italic toggle="yes">Rheumatology</italic> online). Despite the small sample, an absence of outliers at week 12 suggests improvement in the home FVC technique over time.</p>
                <table-wrap position="float" id="keac300-T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Mean change from baseline to day 85 in exploratory efficacy endpoints (per protocol population<xref rid="tblfn6" ref-type="table-fn"><sup>a</sup></xref>)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col valign="top" align="left" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                      <col valign="top" align="center" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th rowspan="1" colspan="1">Efficacy endpoint</th>
                        <th rowspan="1" colspan="1">Placebo (<italic toggle="yes">n</italic> = 8)</th>
                        <th rowspan="1" colspan="1">GSK2330811 300 mg (<italic toggle="yes">n</italic> = 23)</th>
                        <th rowspan="1" colspan="1">Difference from placebo</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td rowspan="1" colspan="1">mRSS</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> <italic toggle="yes">n</italic></td>
                        <td rowspan="1" colspan="1">8</td>
                        <td rowspan="1" colspan="1">21</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Change from baseline, posterior mean (95% CrI)</td>
                        <td rowspan="1" colspan="1">−3.13 (−6.20, −0.07)</td>
                        <td rowspan="1" colspan="1">−2.01 (−3.82, −0.20)</td>
                        <td rowspan="1" colspan="1">1.12 (−2.43, 4.72)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Probability &lt;0, %</td>
                        <td rowspan="1" colspan="1">98</td>
                        <td rowspan="1" colspan="1">98</td>
                        <td rowspan="1" colspan="1">27</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">FVC<sub>lab</sub></td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> <italic toggle="yes">n</italic></td>
                        <td rowspan="1" colspan="1">8</td>
                        <td rowspan="1" colspan="1">20</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Change from baseline, posterior mean (95% CrI)</td>
                        <td rowspan="1" colspan="1">0.04 (−0.20, 0.28)</td>
                        <td rowspan="1" colspan="1">0.06 (−0.09, 0.21)</td>
                        <td rowspan="1" colspan="1">0.02 (−0.27, 0.30)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Probability &gt;0, %</td>
                        <td rowspan="1" colspan="1">64</td>
                        <td rowspan="1" colspan="1">80</td>
                        <td rowspan="1" colspan="1">56</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">ACR CRISS</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> <italic toggle="yes">n</italic></td>
                        <td rowspan="1" colspan="1">6</td>
                        <td rowspan="1" colspan="1">19</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Predicted probability of improvement from baseline, median (IQR)</td>
                        <td rowspan="1" colspan="1">0.11 (0.00, 0.60)</td>
                        <td rowspan="1" colspan="1">0.01 (0.00, 0.06)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">HAQ-DI</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> <italic toggle="yes">n</italic></td>
                        <td rowspan="1" colspan="1">8</td>
                        <td rowspan="1" colspan="1">22</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Change from baseline, posterior mean (95% CrI)</td>
                        <td rowspan="1" colspan="1">0.01 (−0.22, 0.25)</td>
                        <td rowspan="1" colspan="1">0.05 (−0.10, 0.19)</td>
                        <td rowspan="1" colspan="1">0.03 (−0.24, 0.31)</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Probability &lt;0, %</td>
                        <td rowspan="1" colspan="1">45</td>
                        <td rowspan="1" colspan="1">26</td>
                        <td rowspan="1" colspan="1">41</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">PhGA</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> <italic toggle="yes">n</italic></td>
                        <td rowspan="1" colspan="1">8</td>
                        <td rowspan="1" colspan="1">22</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean change from baseline (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">−0.8 (1.67)</td>
                        <td rowspan="1" colspan="1">0.3 (2.45)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1">PtGA</td>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                        <td rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> <italic toggle="yes">n</italic></td>
                        <td rowspan="1" colspan="1">6</td>
                        <td rowspan="1" colspan="1">22</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                      <tr>
                        <td rowspan="1" colspan="1"> Mean change from baseline (<sc>s</sc>.<sc>d</sc>.)</td>
                        <td rowspan="1" colspan="1">1.0 (2.10)</td>
                        <td rowspan="1" colspan="1">0.6 (2.04)</td>
                        <td rowspan="1" colspan="1">–</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="tblfn6">
                      <label>a</label>
                      <p>Data for 100 mg group not shown.</p>
                    </fn>
                    <fn id="tblfn7">
                      <p>CRISS: combined response index for systemic sclerosis; CrI: credible interval; HAQ-DI: HAQ-Disability Index; PhGA: Physician’s Global Assessment; PtGA: Patient’s Global Assessment.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec>
                <title>Safety</title>
                <p>All participants reported at least one adverse event (AE) during the on-treatment phase (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S12</xref>, available at <italic toggle="yes">Rheumatology</italic> online). In the 300 mg group, nine (39%) participants experienced AEs of decreased haemoglobin (5 participants) or anaemia (4 participants). Laboratory values showed dose-dependent reductions in haemoglobin that worsened over time during treatment with GSK2330811 100 mg and 300 mg, with a median time to nadir in the 300 mg group at day 84 (range 16–154) and recovery off-treatment to near baseline by the end of follow-up (<xref rid="keac300-F2" ref-type="fig">Fig. 2A</xref>). Two (25%) participants receiving placebo and 20 (87%) participants receiving 300 mg had an increase (worsening) of at least one grade for anaemia based on the Common Terminology Criteria for AEs (CTCAE). Of these, two (9%) participants receiving 300 mg worsened to grade 3 anaemia (haemoglobin &lt;80 g/l), necessitating discontinuation of treatment as per protocol. However, the CTCAE anaemia grade was imbalanced at baseline, with nine (38%) participants in the 300 mg group having grade 1 anaemia pre-dose [haemoglobin &lt;lower limit of normal (LLN) − 100 g/l] compared with none in the other groups.</p>
                <fig position="float" id="keac300-F2">
                  <label><sc>Fig</sc>. 2</label>
                  <caption>
                    <p>Mean (<bold>A</bold>) blood haemoglobin levels and (<bold>B</bold>) platelet counts (safety population)</p>
                    <p>BL: baseline.</p>
                  </caption>
                  <graphic xlink:href="keac300f2" position="float"/>
                </fig>
                <p>Decrease in mean platelet count was dose dependent. Six (26%) participants experienced AEs of either a platelet count decrease (13%) or thrombocytopenia (13%). In the 300 mg group, nine (39%) participants had an increase (worsening) in thrombocytopenia to grade 1 (platelet count &lt;LLN − 75 × 10<sup>9</sup>/l), with a median time to nadir at day 42 (range 16–84). Platelet counts recovered to baseline values by the end of follow-up (<xref rid="keac300-F2" ref-type="fig">Fig. 2B</xref>). Changes in reticulocyte counts, erythropoietin and thrombopoietin were also treatment group dependent (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S7</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <p>The mean total neutrophil counts decreased in the 300 mg group compared with placebo (<xref rid="sup1" ref-type="supplementary-material">Supplementary Fig. S7D</xref>, available at <italic toggle="yes">Rheumatology</italic> online); three participants (13%) worsened to grade 1 neutropenia (&lt;LLN − 1.5 × 10<sup>9</sup>/l), one participant (4%) worsened to grade 3 neutropenia (&lt;1 − 0.5 × 10<sup>9</sup>/l) and one participant (13%) in the placebo group worsened to grade 2 neutropenia.</p>
                <p>Four (17%) participants in the 300 mg group permanently discontinued study treatment or withdrew from the study due to an AE, compared with none in the placebo or 100 mg group (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S13</xref>, available at <italic toggle="yes">Rheumatology</italic> online).</p>
                <p>During the on-treatment phase, one participant in the 300 mg group experienced serious AEs (SAEs) of atrial fibrillation, mild hypotension and severe pericarditis. During follow-up, one participant in the placebo group experienced an infected digital ulcer. Two participants in the 300 mg group reported SAEs after completing participation in the study: one was diagnosed with urothelial cell cancer 236 days after the last dose and one was diagnosed with renal cell carcinoma 533 days after the last dose of GSK2330811. All SAEs were considered by the investigator to be unrelated or unlikely related to GSK2330811. No participant died during the study.</p>
              </sec>
            </sec>
            <sec>
              <title>Discussion</title>
              <p>As well as being the first repeat-dosing study of the anti-OSM monoclonal antibody GSK2330811 in participants with SSc, this study incorporated innovative study design elements to address well-highlighted challenges of conducting randomized controlled trials in SSc [<xref rid="keac300-B30" ref-type="bibr">30–32</xref>]. The multivariate modelling of predefined, carefully selected biomarkers to assess proof of mechanism avoids an inflated type I error, which can result when considering endpoints independently, and exemplifies the potential of an experimental medicine approach combined with a rigorous statistical framework in complex immune-mediated disease. Assessment of target engagement of GSK2330811 to OSM in the skin compartment using a skin suction blister model [<xref rid="keac300-B15" ref-type="bibr">15</xref>] and home FVC measurement are additional contributions towards innovation in SSc trial design.</p>
              <p>Exposure of GSK2330811 in plasma was consistent with modelled expectations and confirmed target engagement in serum [<xref rid="keac300-B15" ref-type="bibr">15</xref>]. Skin blister fluid data were limited, but demonstrated that GSK2330811 reached the skin. Despite this, proof of mechanism, as measured by a coordinated effect on biomarkers of inflammation and fibrosis in skin and serum, was not demonstrated following treatment with GSK2330811. A correlation between OSM and CRP is well described [<xref rid="keac300-B33" ref-type="bibr">33</xref>], and SOCS3 (a signalling molecule downstream of OSM and IL-6) was downregulated by the IL-6 receptor blocker tocilizumab in the faSScinate study [<xref rid="keac300-B20" ref-type="bibr">20</xref>]. The lack of anticipated effect of GSK2330811 on CRP and SOCS3 implies possible redundancy in OSM signalling (e.g. IL-6). While OSM pathways are known to be activated in fibrosis and SSc [<xref rid="keac300-B10" ref-type="bibr">10</xref>, <xref rid="keac300-B13" ref-type="bibr">13</xref>, <xref rid="keac300-B34" ref-type="bibr">34</xref>], OSM blockade alone may be inadequate to ameliorate dcSSc disease pathology.</p>
              <p>High background use of mycophenolate, which was excluded in faSScinate, may have dampened the effects of GSK2330811. Other hypotheses include the potential for lower GSK2330811 levels in fibrotic skin, leading to insufficient skin target engagement, and differential effects of OSM inhibition on signalling through its two receptors. If the low-affinity leukaemia inhibitory factor receptor (LIFR) mediates haemoglobin and platelet effects, and the high-affinity OSM receptor mediates targeted skin effects, increased OSM inhibition may elicit LIFR-mediated AEs before achieving potentially advantageous inhibition of OSM receptor signalling [<xref rid="keac300-B35" ref-type="bibr">35</xref>].</p>
              <p>The safety of GSK2330811 was not favourable at 300 mg based on the observed degree of anaemia, thrombocytopenia and mild neutropenia. Anaemia and thrombocytopenia are consistent with a known role of OSM in bone marrow [<xref rid="keac300-B36" ref-type="bibr">36–38</xref>] and were reported in the phase 1 study of GSK2330811 in healthy participants [<xref rid="keac300-B15" ref-type="bibr">15</xref>]. However, anaemia was more pronounced than anticipated. Elevation of thrombopoietin and erythropoietin and the time course of reticulocytosis provide mechanistic insights into potential compensatory mechanisms following GSK2330811 treatment.</p>
              <p>The study was limited by the small number of samples available for αSMA analysis; insufficient blister fluid samples for measurement of target engagement; unequal randomization of underlying ILD, FVC, autoantibodies and anaemia at baseline; and high background mycophenolate usage. Most participants were positive for ANA and anti-RNA polymerase III was the most common SSc-specific reactivity, reflecting recruitment of patients with early severe dcSSc in the USA and UK. Generalizability to other ANA subgroups may be limited but is likely irrelevant for interpretation of a negative trial. While 12 weeks was likely too short a treatment period to observe changes in clinical endpoints, in the absence of effects on inflammation and fibrosis biomarkers it is unlikely that a longer study would show clinical efficacy.</p>
              <p>Although these data do not support further clinical development of GSK2330811 in SSc, this study advances our understanding of OSM biology and introduces innovations in early phase clinical study design in SSc.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>keac300_Supplementary_Data</label>
                <media xlink:href="keac300_supplementary_data.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="ack1">
              <title>Acknowledgements</title>
              <p>The authors would like to thank the study participants as well as the study investigators, study coordinators, the study site teams (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref>, available at <italic toggle="yes">Rheumatology</italic> online) and the GlaxoSmithKline study teams. Editorial support (in the form of writing assistance, including preparation of the draft manuscript under the direction and guidance of the authors, collating and incorporating authors’ comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Hayley Butler, at Fishawack Indicia, UK, part of Fishawack Health, and was funded by GlaxoSmithKline.</p>
              <p><italic toggle="yes">Funding</italic>: This study (201247) was funded by GlaxoSmithKline (NCT03041025; Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis).</p>
              <p><italic toggle="yes">Disclosure statement</italic>: C.D. reports grants and personal fees from GlaxoSmithKline and CSL Behring; grants from Inventiva, Servier and Arxx Therapeutics; and personal fees from Bayer, Sanofi, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Corbus, Acceleron and Horizon. D.E.F. reports grants and research fees from Actelion, Amgen, Bristol-Myers Squibb, Corbus, Galapagos GlaxoSmithKline, National Institutes of Health (NIH), Novartis, Pfizer, Sanofi and Roche/Genentech and consultancy fees from Actelion, Amgen, Bristol-Myers Squibb, Corbus, Galapagos Novartis and Pfizer. D.K. reports personal fees from Acceleron, Actelion, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Genentech/Roche, Horizon and Mitsubishi Tanabe Pharma and is Chief Medical Officer of Eicos Sciences, a subsidiary of CiviBioPharma, and has stock options. F.D.G. received research grant support and consultancy fees from AbbVie, AstraZeneca, Boehringer Ingelheim, Capella Biosciences, Chemomab, Kymab, Mitsubishi-Tanabe and Janssen. J.V. reports research grants from the NIH, Rheumatology Research Foundation, TeneoBio, Sun Pharma and Boehringer Ingelheim and consultancy fees from Emerald Therapeutics, Boehringer Ingelheim, TeneoBio, Arxx Therapeutics and Ribon Pharma. L.C. has received consulting fees from Boehringer Ingelheim, Bristol-Myers Squibb, Eicos, Genentech and Mitsubishi-Tanabe and served on the data and safety monitoring board for Reata. S.R.J. reports grants from Bayer, Boehringer Ingelheim and Corbus and consulting fees from Boehringer Ingelheim and Eicos. M.C.V. reports grants and personal fees from Boehringer Ingelheim, Bristol-Myers Squibb, Corbus, GlaxoSmithKline, Janssen, MSD, Novartis and Roche and grants from Boehringer Ingelheim, Ferrer, Galapagos and Janssen. J.T., C.Z., E.C., A.L., N.W., S.M.F. and J.R. are employees of GlaxoSmithKline and hold stock/shares in the company. The study protocol (File S1) was approved by each study site’s ethics committee or institutional review board, in accordance with the ICH, GCP and applicable country-specific requirements.</p>
            </ack>
            <sec sec-type="data-availability">
              <title>Data availability statement</title>
              <p>Anonymised individual participant data and additional study documents can be requested for further research from <ext-link xlink:href="https://www.clinicalstudydatarequest.com" ext-link-type="uri">www.clinicalstudydatarequest.com</ext-link>.</p>
            </sec>
            <sec>
              <title>Supplementary data</title>
              <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Rheumatology</italic> online.</p>
            </sec>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="keac300-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Denton</surname><given-names>CP</given-names></string-name>, <string-name><surname>Khanna</surname><given-names>D.</given-names></string-name></person-group><article-title>Systemic sclerosis</article-title>. <source>Lancet</source><year>2017</year>;<volume>390</volume>:<fpage>1685</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">28413064</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stern</surname><given-names>EP</given-names></string-name>, <string-name><surname>Denton</surname><given-names>CP.</given-names></string-name></person-group><article-title>The pathogenesis of systemic sclerosis</article-title>. <source>Rheum Dis Clin North Am</source><year>2015</year>;<volume>41</volume>:<fpage>367</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">26210124</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B3">
                <label>3</label>
                <mixed-citation publication-type="other"><collab>Electronic Medicines Compendium</collab>. Ofev 100 mg soft capsules. <year>2021</year>. <ext-link xlink:href="https://www.medicines.org.uk/emc/product/1786/smpc" ext-link-type="uri">https://www.medicines.org.uk/emc/product/1786/smpc</ext-link> (14 July 2021, date last accessed).</mixed-citation>
              </ref>
              <ref id="keac300-B4">
                <label>4</label>
                <mixed-citation publication-type="other"><collab>US Food and Drug Administration</collab>. ACTEMRA prescribing information. <year>2021</year>. <ext-link xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125276s131lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125276s131lbl.pdf</ext-link> (27 July 2021, date last accessed).</mixed-citation>
              </ref>
              <ref id="keac300-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sullivan</surname><given-names>KM</given-names></string-name>, <string-name><surname>Goldmuntz</surname><given-names>EA</given-names></string-name>, <string-name><surname>Keyes-Elstein</surname><given-names>L</given-names></string-name></person-group><etal>et al</etal><article-title>Myeloablative autologous stem-cell transplantation for severe scleroderma</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>378</volume>:<fpage>35</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">29298160</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Laar</surname><given-names>JM</given-names></string-name>, <string-name><surname>Farge</surname><given-names>D</given-names></string-name>, <string-name><surname>Sont</surname><given-names>JK</given-names></string-name></person-group><etal>et al</etal><article-title>Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial</article-title>. <source>JAMA</source><year>2014</year>;<volume>311</volume>:<fpage>2490</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">25058083</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname><given-names>SR</given-names></string-name>, <string-name><surname>Furst</surname><given-names>DE.</given-names></string-name></person-group><article-title>Current therapeutic approaches in scleroderma: clinical models of effective antifibrotic therapies</article-title>. <source>Curr Treatm Opt Rheumatol</source><year>2020</year>;<volume>6</volume>:<fpage>382</fpage>–<lpage>93</lpage>.</mixed-citation>
              </ref>
              <ref id="keac300-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Feeney</surname><given-names>M</given-names></string-name>, <string-name><surname>Syed</surname><given-names>F</given-names></string-name>, <string-name><surname>Khan</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>Oncostatin M as a potential molecular target in systemic sclerosis</article-title>. <source>Arthritis Rheumatol</source><year>2015</year>;<volume>67</volume>: <fpage>2297</fpage>–<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="keac300-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stifano</surname><given-names>G</given-names></string-name>, <string-name><surname>Sornasse</surname><given-names>T</given-names></string-name>, <string-name><surname>Rice</surname><given-names>LM</given-names></string-name></person-group><etal>et al</etal><article-title>Skin gene expression is prognostic for the trajectory of skin disease in patients with diffuse cutaneous systemic sclerosis</article-title>. <source>Arthritis Rheumatol</source><year>2018</year>;<volume>70</volume>:<fpage>912</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">29858547</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marden</surname><given-names>G</given-names></string-name>, <string-name><surname>Wan</surname><given-names>Q</given-names></string-name>, <string-name><surname>Wilks</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>The role of the oncostatin M/OSM receptor beta axis in activating dermal microvascular endothelial cells in systemic sclerosis</article-title>. <source>Arthritis Res Ther</source><year>2020</year>;<volume>22</volume>:<fpage>179</fpage>.<pub-id pub-id-type="pmid">32736577</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ayaub</surname><given-names>EA</given-names></string-name>, <string-name><surname>Dubey</surname><given-names>A</given-names></string-name>, <string-name><surname>Imani</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Overexpression of OSM and IL-6 impacts the polarization of pro-fibrotic macrophages and the development of bleomycin-induced lung fibrosis</article-title>. <source>Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>13281</fpage>.<pub-id pub-id-type="pmid">29038604</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Botelho</surname><given-names>FM</given-names></string-name>, <string-name><surname>Rodrigues</surname><given-names>R</given-names></string-name>, <string-name><surname>Guerette</surname><given-names>J</given-names></string-name></person-group><etal>et al</etal><article-title>Extracellular matrix and fibrocyte accumulation in BALB/c mouse lung upon transient overexpression of oncostatin M</article-title>. <source>Cells</source><year>2019</year>;<volume>8</volume>:<fpage>126</fpage>.<pub-id pub-id-type="pmid">30764496</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mozaffarian</surname><given-names>A</given-names></string-name>, <string-name><surname>Brewer</surname><given-names>AW</given-names></string-name>, <string-name><surname>Trueblood</surname><given-names>ES</given-names></string-name></person-group><etal>et al</etal><article-title>Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis</article-title>. <source>J Immunol</source><year>2008</year>;<volume>181</volume>:<fpage>7243</fpage>–<lpage>53</lpage>.<pub-id pub-id-type="pmid">18981146</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matsuda</surname><given-names>M</given-names></string-name>, <string-name><surname>Tsurusaki</surname><given-names>S</given-names></string-name>, <string-name><surname>Miyata</surname><given-names>N</given-names></string-name></person-group><etal>et al</etal><article-title>Oncostatin M causes liver fibrosis by regulating cooperation between hepatic stellate cells and macrophages in mice</article-title>. <source>Hepatology</source><year>2018</year>;<volume>67</volume>:<fpage>296</fpage>–<lpage>312</lpage>.<pub-id pub-id-type="pmid">28779552</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reid</surname><given-names>J</given-names></string-name>, <string-name><surname>Zamuner</surname><given-names>S</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>K</given-names></string-name></person-group><etal>et al</etal><article-title>In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody</article-title>. <source>Br J Clin Pharmacol</source><year>2018</year>;<volume>84</volume>:<fpage>2280</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">29900565</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Allanore</surname><given-names>Y</given-names></string-name>, <string-name><surname>Distler</surname><given-names>O</given-names></string-name>, <string-name><surname>Jagerschmidt</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double-blind, randomized, eight-week placebo-controlled study followed by a sixteen-week open-label extension study</article-title>. <source>Arthritis Rheumatol</source><year>2018</year>;<volume>70</volume>:<fpage>1634</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">29732731</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Denton</surname><given-names>CP</given-names></string-name>, <string-name><surname>Ong</surname><given-names>VH</given-names></string-name>, <string-name><surname>Xu</surname><given-names>S</given-names></string-name></person-group><etal>et al</etal><article-title>Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis</article-title>. <source>Ann Rheum Dis</source><year>2018</year>;<volume>77</volume>:<fpage>1362</fpage>–<lpage>71</lpage>.<pub-id pub-id-type="pmid">29853453</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nagahama</surname><given-names>KY</given-names></string-name>, <string-name><surname>Togo</surname><given-names>S</given-names></string-name>, <string-name><surname>Holz</surname><given-names>O</given-names></string-name></person-group><etal>et al</etal><article-title>Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3</article-title>. <source>Am J Respir Cell Mol Biol</source><year>2013</year>;<volume>49</volume>:<fpage>582</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">23668543</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rice</surname><given-names>LM</given-names></string-name>, <string-name><surname>Padilla</surname><given-names>CM</given-names></string-name>, <string-name><surname>McLaughlin</surname><given-names>SR</given-names></string-name></person-group><etal>et al</etal><article-title>Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients</article-title>. <source>J Clin Invest</source><year>2015</year>;<volume>125</volume>:<fpage>2795</fpage>–<lpage>807</lpage>.<pub-id pub-id-type="pmid">26098215</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khanna</surname><given-names>D</given-names></string-name>, <string-name><surname>Denton</surname><given-names>CP</given-names></string-name>, <string-name><surname>Jahreis</surname><given-names>A</given-names></string-name></person-group><etal>et al</etal><article-title>Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial</article-title>. <source>Lancet</source><year>2016</year>;<volume>387</volume>:<fpage>2630</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">27156934</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rice</surname><given-names>LM</given-names></string-name>, <string-name><surname>Ziemek</surname><given-names>J</given-names></string-name>, <string-name><surname>Stratton</surname><given-names>EA</given-names></string-name></person-group><etal>et al</etal><article-title>A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis</article-title>. <source>Arthritis Rheumatol</source><year>2015</year>;<volume>67</volume>:<fpage>3004</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">26240058</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abignano</surname><given-names>G</given-names></string-name>, <string-name><surname>Blagojevic</surname><given-names>J</given-names></string-name>, <string-name><surname>Bissell</surname><given-names>LA</given-names></string-name></person-group><etal>et al</etal><article-title>European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis</article-title>. <source>Rheumatology</source><year>2019</year>;<volume>58</volume>:<fpage>254</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">30239834</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abignano</surname><given-names>G</given-names></string-name>, <string-name><surname>Cuomo</surname><given-names>G</given-names></string-name>, <string-name><surname>Buch</surname><given-names>MH</given-names></string-name></person-group><etal>et al</etal><article-title>The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis</article-title>. <source>Ann Rheum Dis</source><year>2014</year>;<volume>73</volume>:<fpage>420</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">23511226</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akesson</surname><given-names>A</given-names></string-name>, <string-name><surname>Scheja</surname><given-names>A</given-names></string-name>, <string-name><surname>Lundin</surname><given-names>A</given-names></string-name>, <string-name><surname>Wollheim</surname><given-names>FA.</given-names></string-name></person-group><article-title>Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide</article-title>. <source>Arthritis Rheum</source><year>1994</year>;<volume>37</volume>:<fpage>729</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">8185701</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duncan</surname><given-names>MR</given-names></string-name>, <string-name><surname>Hasan</surname><given-names>A</given-names></string-name>, <string-name><surname>Berman</surname><given-names>B.</given-names></string-name></person-group><article-title>Oncostatin M stimulates collagen and glycosaminoglycan production by cultured normal dermal fibroblasts: insensitivity of sclerodermal and keloidal fibroblasts</article-title>. <source>J Invest Dermatol</source><year>1995</year>;<volume>104</volume>:<fpage>128</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">7798630</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname><given-names>X</given-names></string-name>, <string-name><surname>Higgs</surname><given-names>BW</given-names></string-name>, <string-name><surname>Bay-Jensen</surname><given-names>AC</given-names></string-name></person-group><etal>et al</etal><article-title>Suppression of T cell activation and collagen accumulation by an anti-IFNAR1 mAb, anifrolumab, in adult patients with systemic sclerosis</article-title>. <source>J Invest Dermatol</source><year>2015</year>;<volume>135</volume>:<fpage>2402</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">25993119</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Shin</surname><given-names>KC</given-names></string-name>, <string-name><surname>Kang</surname><given-names>SW</given-names></string-name></person-group><etal>et al</etal><article-title>Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis</article-title>. <source>Clin Exp Rheumatol</source><year>2001</year>;<volume>19</volume>:<fpage>69</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">11247328</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Quillinan</surname><given-names>NP</given-names></string-name>, <string-name><surname>McIntosh</surname><given-names>D</given-names></string-name>, <string-name><surname>Vernes</surname><given-names>J</given-names></string-name>, <string-name><surname>Haq</surname><given-names>S</given-names></string-name>, <string-name><surname>Denton</surname><given-names>CP.</given-names></string-name></person-group><article-title>Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial</article-title>. <source>Ann Rheum Dis</source><year>2014</year>;<volume>73</volume>:<fpage>56</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">24067785</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Assassi</surname><given-names>S</given-names></string-name>, <string-name><surname>Wu</surname><given-names>M</given-names></string-name>, <string-name><surname>Tan</surname><given-names>FK</given-names></string-name></person-group><etal>et al</etal><article-title>Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis</article-title>. <source>Arthritis Rheum</source><year>2013</year>;<volume>65</volume>:<fpage>2917</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">23897225</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname><given-names>SR</given-names></string-name>, <string-name><surname>Hinchcliff</surname><given-names>M</given-names></string-name>, <string-name><surname>Asano</surname><given-names>Y.</given-names></string-name></person-group><article-title>Controversies: molecular vs. clinical systemic sclerosis classification</article-title>. <source>J Scleroderma Relat Disord</source><year>2016</year>;<volume>1</volume>:<fpage>277</fpage>–<lpage>85</lpage>.</mixed-citation>
              </ref>
              <ref id="keac300-B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname><given-names>SR</given-names></string-name>, <string-name><surname>Khanna</surname><given-names>D</given-names></string-name>, <string-name><surname>Allanore</surname><given-names>Y</given-names></string-name>, <string-name><surname>Matucci-Cerinic</surname><given-names>M</given-names></string-name>, <string-name><surname>Furst</surname><given-names>DE.</given-names></string-name></person-group><article-title>Systemic sclerosis trial design moving forward</article-title>. <source>J Scleroderma Relat Disord</source><year>2016</year>;<volume>1</volume>:<fpage>177</fpage>–<lpage>80</lpage>.</mixed-citation>
              </ref>
              <ref id="keac300-B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Johnson</surname><given-names>SR</given-names></string-name>, <string-name><surname>Tomlinson</surname><given-names>GA</given-names></string-name>, <string-name><surname>Granton</surname><given-names>JT</given-names></string-name>, <string-name><surname>Hawker</surname><given-names>GA</given-names></string-name>, <string-name><surname>Feldman</surname><given-names>BM.</given-names></string-name></person-group><article-title>Applied Bayesian methods in the rheumatic diseases</article-title>. <source>Rheum Dis Clin North Am</source><year>2018</year>;<volume>44</volume>:<fpage>361</fpage>–<lpage>70</lpage>.<pub-id pub-id-type="pmid">29622302</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Akarsu</surname><given-names>M</given-names></string-name>, <string-name><surname>Hurşitoğlu</surname><given-names>M</given-names></string-name>, <string-name><surname>Toprak</surname><given-names>Z</given-names></string-name></person-group><etal>et al</etal><article-title>Relationships among oncostatin M, insulin resistance, and chronic inflammation: a pilot study</article-title>. <source>Arch Endocrinol Metab</source><year>2020</year>;<volume>64</volume>:<fpage>38</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">31576964</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stawski</surname><given-names>L</given-names></string-name>, <string-name><surname>Trojanowska</surname><given-names>M.</given-names></string-name></person-group><article-title>Oncostatin M and its role in fibrosis</article-title>. <source>Connect Tissue Res</source><year>2019</year>;<volume>60</volume>:<fpage>40</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">30056769</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gearing</surname><given-names>DP</given-names></string-name>, <string-name><surname>Bruce</surname><given-names>AG.</given-names></string-name></person-group><article-title>Oncostatin M binds the high-affinity leukemia inhibitory factor receptor</article-title>. <source>New Biol</source><year>1992</year>;<volume>4</volume>:<fpage>61</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">1536831</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miyajima</surname><given-names>A</given-names></string-name>, <string-name><surname>Kinoshita</surname><given-names>T</given-names></string-name>, <string-name><surname>Tanaka</surname><given-names>M</given-names></string-name></person-group><etal>et al</etal><article-title>Role of oncostatin M in hematopoiesis and liver development</article-title>. <source>Cytokine Growth Factor Rev</source><year>2000</year>;<volume>11</volume>:<fpage>177</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">10817961</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tanaka</surname><given-names>M</given-names></string-name>, <string-name><surname>Hirabayashi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sekiguchi</surname><given-names>T</given-names></string-name></person-group><etal>et al</etal><article-title>Targeted disruption of oncostatin M receptor results in altered hematopoiesis</article-title>. <source>Blood</source><year>2003</year>;<volume>102</volume>:<fpage>3154</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">12855584</pub-id></mixed-citation>
              </ref>
              <ref id="keac300-B38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wallace</surname><given-names>PM</given-names></string-name>, <string-name><surname>Macmaster</surname><given-names>JF</given-names></string-name>, <string-name><surname>Rillema</surname><given-names>JR</given-names></string-name></person-group><etal>et al</etal><article-title>In vivo properties of oncostatin M</article-title>. <source>Ann N Y Acad Sci</source><year>1995</year>;<volume>762</volume>:<fpage>42</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">7545375</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
